Acadia Pharmaceuticals Inc. (ACAD)

[IanFromSI]

And here's one from only 2 days ago...


ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from SVB Securities
July 11 2022 - 08:39AM

In a report released today, Marc Goodman from SVB Securities maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $27.00. The company's shares closed last Friday at $15.74.

ACADIA Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $22.64, representing a 45.7% upside.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-rating-from-svb-securities?utm_source=advfn.com&utm_medium=referral

[IanFromSI]

- If you really need to go all the way back to June 21st, here's another analyst on that same day.


ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from JMP Securities
June 21 2022 - 08:26AM
TipRanks

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $23.00. The company's shares closed last Thursday at $19.51.

Currently, the analyst consensus on ACADIA Pharmaceuticals is a Moderate Buy with an average price target of $27.17, a 39.4% upside from current levels.
https://www.tipranks.com/news/blurbs/acadia-pharmaceuticals-acad-gets-a-buy-rating-from-jmp-securities?utm_source=advfn.com&utm_medium=referral

[gi197845]

Steve Davis knew that submitting the sNDA a 2nd time for ADP, without any new information, without any additional data, without any changes and without explaining anything positive to the Adcom, that it would be rejected again and that it would crash the stock price, so that's why he sold so much stock recently. Perhaps after 8/4/22, he will buy shares back at $7 ? Only to fumble more and more later, with an opened-shirt and flabby belly hanging out during the conference call meetings.

[gi197845]

Jefferies Financial Group cut shares of ACADIA Pharmaceuticals from a "buy" rating to an "underperform" rating and decreased their price objective for the company from $25.00 to $10.00 in a report on Tuesday, June 21st.

[gi197845]

How much have you lost on Acadia? I mean thus far? How much more will you lose after the 8/4/22 PDFU date?

[IanFromSI]

Interest rates will probably continue to rise for the rest of my life time -- which means that bond prices will fall. For the last 2 centuries, each upleg or downleg in the bond rate cycle has lasted from 21 - 36 years.

I hold no bonds and don't intend to do so again.

Small cap biotechs are speculative by nature. 1 win allows me to have several losses. I don't speculate with rent money or any funds that I may require.

But I do like this sector and will continue to make investments.

[blue finch]

Too
Many failures in this current FDA environment

In fact best money invested in bonds or fixed income

[IanFromSI]

If you look at the post that I was replying to, it seemed to come from someone who is either not suited to biotech investing or has no concept of risk / reward.

Even with a blue chip one can never guarantee absolutely that every purchase will absolutely result in a profit. The poster seemed to demand that.

[blue finch]

I'd stay away from any less than optimal bio

What are you suggesting ?

Buy blue chips ?

[georgejjl]

You may want to reevaluate your investments tomorrow.

www.anavex.com/_files/ugd/850d88_6d847f744209465f82a4ad655bb25941.pdf

www.anavex.com/_files/ugd/79bcf7_02b343eb47da4dfcb7e099f378b3b5f4.pdf

www.youtube.com/watch?v=8orzf4UXNLA

Your investments are your decision.

Good luck and GOD bless,

[IanFromSI]

If you want a 110% certainty, don't speculate in small to mid cap biotechs ever.

[blue finch]

Why risk it
Unless you’re 110% sure you’re getting g approval

Why risk it ?

[georgejjl]

Do you remember the FDA advisory panel vote regarding Biogen's aducanumab?

...the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for Study 301 (ENGAGE), provide strong evidence that supports the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”. The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, and 5 yes, 0 no and 6 uncertain on the question, “Has the Applicant presented strong evidence of a pharmacodynamic effect of aducanumab on Alzheimer’s disease pathophysiology?”. Finally, the Advisory Committee voted 0 yes, 10 no and 1 uncertain on the question, “In light of the understanding provided by the exploratory analyses of Study 301 and Study 302, along with the results of Study 103 and evidence of a pharmacodynamic effect on Alzheimer’s disease pathophysiology, it is reasonable to consider Study 302 as primary evidence of effectiveness of aducanumab for the treatment of Alzheimer’s disease?”...

The Food and Drug Administration on Monday approved the first new medication for Alzheimer’s disease in nearly two decades, a contentious decision made despite opposition from the agency’s independent advisory committee and some Alzheimer’s experts who said there was not enough evidence that the drug can help patients.

Good luck and GOD bless,

[georgejjl]

You may want to reevaluate your investments tomorrow.

https://www.anavex.com/_files/ugd/79bcf7_02b343eb47da4dfcb7e099f378b3b5f4.pdf

Your investments are your decision.

Good luck and GOD bless,

[georgejjl]

FDA Panel Votes Against Acadia (ACAD) sNDA for Nuplazid

https://www.nasdaq.com/articles/fda-panel-votes-against-acadia-acad-snda-for-nuplazid

Good luck and GOD bless,

[IanFromSI]

Yes, The company's PR and the Seeking Alpha coverage are in the Ihub news coverage shown in this thread.

While disappointing, it's almost par for the course.

There's still a significant unmet medical need where the alternative (off label use of anti-psychotics) frequently causing irreversible harm turning patients into near vegetables and completely removing any quality of life. Sort of a Lose-Lose-Lose for the doctors, patients and families.

Nuplazid helps about a third of patients substantially improving quality of life for that subset. For that third, the Psychosis and MDD is successfully treated. - almost a miracle drug for that subset.

For PDP prospective patients, ACAD gave the first 30 days Nuplazid supply free allowing the doctors and patients to determine if it was an effective tx for each pt.

Hopefully, for the patients and their families, a similar approach would allow the FDA to conditionally approve - substantially improving quality of life, but only for about a 1/3 of patients.
After the BIIB fiasco, where the FDA approved a drug that just didn't work at all for any patient (AD), they're probably a bit gunshy re not taking Adcom advice.

We'll find out in August.

[north40000]

AdCom voted 9-3 against approval AH on Friday. PDUFA date remains 8/4/2022.

[IanFromSI]

FDA Says 'No Key Safety Issue' on ACADIA Pharmaceuticals' Resubmitted Application for Pimavanserin
2022-06-15 12:43:56 PM ET (MT Newswires)



12:43 PM EDT, 06/15/2022 (MT Newswires) -- The US Food and Drug Administration said in a briefing document that it has "no key safety issue" to raise before the psychopharmacologic drugs advisory committee regarding ACADIA Pharmaceuticals' (ACAD) resubmitted supplemental new drug application for pimavanserin.

Pimavanserin is an experimental psychosis drug for patients with Alzheimer's disease.

In a clinical trial with 392 participants, the most common adverse reactions include peripheral edema and confusional state, according to the FDA.

The regulator had previously set a target action date of Aug. 4 for the supplemental NDA.

[IanFromSI]

Acadia rises as FDA posts briefing docs ahead of AdCom meeting on antipsychotic therapy
The shares of the commercial-stage biotech Acadia Pharmaceuticals (NASDAQ:ACAD) surged ~29% in the Wednesday after the FDA published briefing documents on antipsychotic therapy pimavanserin targeted at patients with Alzheimer’s disease.
A group of independent experts advising the agency are set to meet on Friday to discuss the approvability of the drug as a treatment for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
The FDA's advisory committees issue non-binding recommendations. However, the regulator usually follows them before making a final decision on authorizations.
Pimavanserin is currently marketed as Nuplazid for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
The FDA has assigned an action date for August 04 to review the marketing application for the new indication.  

[gi197845]

Uh Oh! The Baker Brothers filed to sell 42,393,855 shares of common stock. Ask yourself, why would the Baker Brothers get out? Well, the must have realized that Acadia is a disaster and going downhill, sinking, much like the Titanic?

[gi197845]

Ok, so no voting on the dilution, just make the dilution happen?

[gi197845]

Uh oh, massive shelf offering!! Look out below!

https://ih.advfn.com/stock-market/NASDAQ/acadia-pharmaceuticals-ACAD/stock-news/88213793/automatic-shelf-registration-statement-of-securiti

[gi197845]

Ok, so what you're saying is that with this mass dilution, it will lower the stock price even more, below the resistance level, so that even if the FDA approved Nuplazid for APD, that the stock price would still go lower, due to the massive and irresponsible dilution and that Acadia does not care in the slightest bit for their retail investors?

[gi197845]

It's a briefing.com article

https://www.etrade.wallst.com/v1/news/marketnews/marketnews.asp?ChallengeUrl=https://idp.etrade.com/idp/SSO.saml2&reinitiate-handshake=0&AuthnContext=authenticated&env=PRD&docKey=309-IN20220525163254ACAD_live-5RT2CJ2R01C4B9D1HBJUHQTDSN&DMSourceID=BRIEFING&Source=Briefing.com&DisplayName=Briefing.com&docDate=2022-05-25%2020%3A32%3A54&headline=ACADIA%20Pharmaceuticals%20files%20for%2042%2C393%2C855%20share%20common%20stock%20offering%20by%20selling%20shareholders

[gi197845]

https://www.tipranks.com/news/article/acadia-pharmaceuticals-no-upturn-in-sight?utm_source=advfn.com&utm_medium=referral

[gi197845]

As of 05/25/22
Support 15.16
Resistance 16.82
Stop loss 13.73

[IanFromSI]

Also, Nuplazid will be approve for Schizophrenia! We are going to win, for the benefit of the suffering patients and for our benefit as well!

There's a major unmet medical need here. Latest generation of anti-psychotics have devastating side effects and in most cases leave the pts much worse off, some times permanently.
if Nuplazid could help that subset of pts with hallucinations and delusions, it would be welcomed by pts, families and doctors.

I haven't looked at any trial results, so I have no idea whether this should or could happen any time soon.

[gi197845]

No, I'm not paid for any posts. I have changed my negative ways! The curse has been lifted, by the blood of Jesus! Let's the blessings pour out upon us!!!
Restore what has been lost!
Make us Whole!
Amen!

[gi197845]

Give me the link to the biotech values board or I will search for it!

[IanFromSI]

I repeat, " Are you being compensated in any fashion for the misinformation that you post here?" If so, by whom?

[gi197845]

Good points Ian and you're right! Rock n' Roll with Acadia pharma! Improving the lives of patients and improving the lives of confident investors!

[gi197845]

A new revelation! Acadia will be successful very soon! Just hold on! This 2nd time around, Nuplazid will receive approval for ADP. The treatment for RETT syndrome will also be approved soon! Also, Nuplazid will be approve for Schizophrenia! We are going to win, for the benefit of the suffering patients and for our benefit as well! Rock n' Roll with Acadia! The Baker Brothers ROCK!!!

[IanFromSI]

Why do you waste your time on this board? It has less than 10th of the users that the biotech board has, and about 1000th of the posts that the biotech values board has.

Are you being compensated to spread disinformation?

Nuplazid significantly improves the quality of life for PDP patients that are nearing the end of their days. Getting rid of hallucinations and delusions, as well as curing MDD in about a third of the patients is just a fabulous benefit for the patients and their families.

Acadia delivered these benefits to PDP patients and their families. There’s a desperate need to deliver a similar set of benefits to the ADP patients.

That is the opposite of the Biogen fiasco. Biogen had 2 phase threes. One showed no benefits, the other failed miserably. The Adcom was almost unanimous in voting against approval.

When the FDA approved Aduhelm, 3 adcom members resigned in disgust.

This bears absolutely no resemblance to the approval process for Nuplazid whether we’re talking about PDP or ADP.

I don’t have the actual statistics, but I believe that Alzheimer’s disease progresses to death faster than PDP. The improved quality of life which Nuplazid would deliver is very much needed by this group of patients. I fully expect that Nuplazid will be approved for ADP and millions of families will benefit as a result.

But what do I know?

Ian

[gi197845]

Ok, so Acadia is a one trick pony with Nuplazid and as the elderly patient base passes, new patients are slow to fill the lacking patient base. Nuplazid is not something that young patients stay on for their entire lives for a full profit. Also, Nuplzid can be prescribed off label, so new indication may not increase profits by much. Also, all indication are that the FDA will reject Nuplazid for ADP, do to the Biogen fiasco...Also the med for Rett syndrome has not been approved and it has a small patient base anyway. There are already several meds for schizophrenia treatment. I think the only way to boost profits is to cut the BOD pay on half and for Acadia to seek EU approval for Nuplazid. All indicators appear to show that Acadia is headed into the single digits. Also, the open and un buttoned shirt, style of management by Steve Davis is lackluster at best, especially when he couldn't even answer how is going to deal with the advisory panels objections and recommendation to for a 2nd time, to reject Nuplazid for ADP. We're through the looking glass here folks, all indication are that we are headed for bankruptcy, let's face it, Acadia is 3rd on the Baker Brothers list of holdings, meaning it's the ugly, red-headed step child, which gets no positive attention. Also, Acadia can't pay for another round of ADP trials, without a severe dilution if shares, or worse yet, a reverse split! Now combine that with high inflation, higher interest rates, high gas prices and the increased government take over of health care and big pharma, price controls to lower profits! Also, the BOD members selling off shares of their stock!

[gi197845]

My average price per share, or pps is $26.55, do'h!
Thanks Harrybumb!

[gi197845]

https://ih.advfn.com/stock-market/NASDAQ/acadia-pharmaceuticals-ACAD/stock-news/88148413/acadia-pharmaceuticals-no-upturn-in-sight

Uh oh!

[gi197845]

Don't blame me, I voted for mean tweets and $1.89 per gallon gasoline.

[gi197845]

Buy! Buy! Buy!!!

[gi197845]

Look out below!

[gi197845]

LOL, $15.05 after hours now!

[gi197845]

Have you taken to shorting ACAD? Or are you a buy, buy, buy, guy now? You do release that the shorts have increased their position, right? You do realize that when this goes even much lower, after a 2nd Joe Biden FDA rejection, that a reverse split is coming that will wipe out any potential profit you had, right...Right, genius?

[gi197845]

How much are you down on ACAD, AVEO and POTN?

[harry crumb]

U hav no clue loser

[harry crumb]

Get lost loser

[gi197845]

Harry Bumb, Buy, Buy, Buy!!! and vote again for JB or KAMALA! Apparently you've never been through a recession or a depression! Keep investing in penny stock picks, penny stock picks! Waterless toothbrush from a used car salesmen! LOOOOOL!

[gi197845]

Buy, buy, buy, before the dilution, before the reverse split, before the FDA rejection, before the recession turns to a great democrat reset depression!

[gi197845]

If they drop this to -5$ I'm a buyer!!!

[gi197845]

Buy, buy, buy @ $16.69 now!

[gi197845]

LOL, you were so wrong as usual! It's so far below 22/21, so you need to load! Load now and vote JB! Sell your lots for less then you bout them for, libby!

[gi197845]

Buy more Harry Crumb, catch this falling knife, invest life's saving!